Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
For this indication, competent medicine agencies globally authorize below treatments:
Oral
80 - 125 mg
From 80 To 125 mg once every day
125 mg
80 mg
Aprepitant is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning
The following regimens are recommended in adults for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.
Highly Emetogenic Chemotherapy Regimen:
| Day 1 | Day 2 | Day 3 | Day 4 | |
|---|---|---|---|---|
| Aprepitant | 125 mg orally | 80 mg orally | 80 mg orally | none |
| Dexamethasone | 12 mg orally | 8 mg orally | 8 mg orally | 8 mg orally |
| 5-HT3 antagonists | Standard dose of 5-HT3 antagonists. See the product information for the selected 5-HT3 antagonist for ppropriate dosing nformation | none | none | none |
Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. The dose of dexamethasone accounts for active substance interactions.
Moderately Emetogenic Chemotherapy Regimen:
| Day 1 | Day 2 | Day 3 | |
|---|---|---|---|
| Aprepitant | 125 mg orally | 80 mg orally | 80 mg orally |
| Dexamethasone | 12 mg orally | none | none |
| 5-HT3 antagonists | Standard dose of 5-HT3 antagonists. See the product information for the selected 5-HT3 antagonist for appropriate dosing information | none | none |
Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for active substance interactions.